Truist Financial Issues Pessimistic Forecast for Hims & Hers Health (NYSE:HIMS) Stock Price

Hims & Hers Health (NYSE:HIMS) had its target price decreased by research analysts at Truist Financial from $48.00 to $37.00 in a research note issued to investors on Monday,Benzinga reports. The firm currently has a “hold” rating on the stock. Truist Financial’s target price would indicate a potential downside of 12.27% from the company’s current price.

Several other brokerages have also issued reports on HIMS. Piper Sandler reiterated a “neutral” rating and set a $39.00 price target (up from $35.00) on shares of Hims & Hers Health in a report on Tuesday, May 6th. TD Cowen lowered Hims & Hers Health from a “buy” rating to a “hold” rating and reduced their target price for the stock from $44.00 to $30.00 in a report on Tuesday, April 29th. Wall Street Zen lowered Hims & Hers Health from a “buy” rating to a “hold” rating in a report on Monday, July 28th. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Hims & Hers Health in a report on Wednesday, May 7th. Finally, Needham & Company LLC restated a “hold” rating on shares of Hims & Hers Health in a report on Tuesday, August 5th. Two research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Reduce” and a consensus target price of $38.92.

Hims & Hers Health Trading Down 6.5%

NYSE:HIMS opened at $42.1760 on Monday. The stock has a market cap of $9.53 billion, a PE ratio of 52.72, a price-to-earnings-growth ratio of 2.86 and a beta of 2.08. The company has a debt-to-equity ratio of 1.72, a current ratio of 4.98 and a quick ratio of 4.46. Hims & Hers Health has a fifty-two week low of $13.47 and a fifty-two week high of $72.98. The stock’s 50-day moving average is $52.47 and its two-hundred day moving average is $45.75.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.01). The firm had revenue of $544.83 million for the quarter, compared to analyst estimates of $550.06 million. Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The firm’s quarterly revenue was up 72.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.06 earnings per share. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, equities research analysts forecast that Hims & Hers Health will post 0.29 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Michael Chi sold 17,102 shares of the company’s stock in a transaction that occurred on Tuesday, June 17th. The stock was sold at an average price of $59.75, for a total transaction of $1,021,844.50. Following the completion of the transaction, the insider directly owned 278,654 shares in the company, valued at $16,649,576.50. The trade was a 5.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Andrew Dudum sold 660,000 shares of the company’s stock in a transaction that occurred on Thursday, August 7th. The stock was sold at an average price of $50.58, for a total value of $33,382,800.00. Following the transaction, the chief executive officer owned 2,214,769 shares of the company’s stock, valued at approximately $112,023,016.02. This trade represents a 22.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,273,034 shares of company stock valued at $66,425,573 in the last three months. 17.71% of the stock is owned by corporate insiders.

Institutional Trading of Hims & Hers Health

A number of institutional investors and hedge funds have recently modified their holdings of the company. Smartleaf Asset Management LLC increased its position in shares of Hims & Hers Health by 15.7% during the first quarter. Smartleaf Asset Management LLC now owns 1,672 shares of the company’s stock valued at $49,000 after purchasing an additional 227 shares during the period. Bessemer Group Inc. increased its position in shares of Hims & Hers Health by 105.8% during the second quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock valued at $30,000 after purchasing an additional 312 shares during the period. True Vision MN LLC increased its position in shares of Hims & Hers Health by 3.6% during the second quarter. True Vision MN LLC now owns 9,376 shares of the company’s stock valued at $467,000 after purchasing an additional 328 shares during the period. Allworth Financial LP increased its position in shares of Hims & Hers Health by 20.0% during the first quarter. Allworth Financial LP now owns 2,006 shares of the company’s stock valued at $56,000 after purchasing an additional 334 shares during the period. Finally, Signaturefd LLC increased its position in shares of Hims & Hers Health by 17.7% during the first quarter. Signaturefd LLC now owns 2,586 shares of the company’s stock valued at $76,000 after purchasing an additional 388 shares during the period. 63.52% of the stock is currently owned by institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.